高糖抑制AMPKα2通过促进线粒体相关内质网膜形成诱导糖尿病心肌病
研究探讨Fundc1和线粒体相关内质网膜(MAMs)在糖尿病心脏中的作用。发现糖尿病患者心脏中FUNDC1水平升高,高糖通过抑制AMPK增加Fundc1,促进MAM形成和线粒体功能障碍;心肌细胞特异性敲除Fundc1可改善糖尿病小鼠心脏功能。
要点
- 糖尿病心脏中FUNDC1表达升高,促进MAM形成和线粒体钙超载。
- 心肌细胞敲除Fundc1可减轻糖尿病诱导的线粒体功能障碍和心肌病。
- AMPK抑制是Fundc1上调的上游机制,激活AMPK可消除高糖诱导的MAM形成。
核心结论
- 糖尿病通过抑制AMPK,上调Fundc1,促进MAM形成和线粒体功能障碍,导致心肌病。
- AMPK诱导的Fundc1抑制是治疗糖尿病心肌病的潜在靶点。
研究设计与样本
- 检查糖尿病患者和非糖尿病供体心脏中FUNDC1水平。
- 在高糖(30 mmol/L d-葡萄糖48小时)处理的乳鼠心肌细胞中检测Fundc1、Ip3r2和MAMs。
- 使用链脲佐菌素处理的心脏特异性Fundc1敲除小鼠和心脏特异性Fundc1敲除的糖尿病Akita小鼠。
主要发现
- 糖尿病患者心脏组织中FUNDC1水平显著高于非糖尿病供体。
- 高糖增加乳鼠心肌细胞中Fundc1、Ip3r2和MAMs水平;下调Fundc1或Ip3r2抑制MAM形成,减少内质网-线粒体Ca2+流,改善线粒体功能。
- 腺病毒过表达Fundc1在正常葡萄糖(5.5 mmol/L)下促进MAM形成、线粒体Ca2+增加和线粒体功能障碍。
- 链脲佐菌素处理小鼠和Akita小鼠心脏中Fundc1、Ip3r2和MAMs水平显著增加,且Fundc1与Ip3r2共免疫沉淀增加。
- Fundc1与Ip3r2结合抑制Ip3r2泛素化和蛋白酶体降解。
临床怎么用
- 糖尿病心肌病中可考虑靶向AMPK-Fundc1-MAM通路。
- Fundc1和MAM形成可能成为糖尿病心肌病的生物标志物或治疗靶点。
局限性
- 研究主要基于动物模型和细胞实验,需进一步临床验证。
- 未明确MAM形成的具体阈值或剂量效应关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fundc1 (FUN14 domain containing 1), an outer mitochondrial membrane protein, is important for mitophagy and mitochondria-associated endoplasmic reticulum membranes (MAMs). The roles of Fundc1 and MAMs in diabetic hearts remain unknown. The aims of this study, therefore, were to determine whether the diabetes mellitus-induced Fundc1 expression could increase MAM formation, and whether disruption of MAM formation improves diabetic cardiac function. METHODS: Levels of FUNDC1 were examined in the hearts from diabetic patients and nondiabetic donors. Levels of Fundc1-induced MAMs and mitochondrial and heart function were examined in mouse neonatal cardiomyocytes exposed to high glucose (HG, 30 mmol/L d-glucose for 48 hours), and in streptozotocin-treated cardiac-specific Fundc1 knockout mice and cardiac-specific Fundc1 knockout diabetic Akita mice, as well. RESULTS: FUNDC1 levels were significantly elevated in cardiac tissues from diabetic patients in comparison with those from nondiabetic donors. In cultured mouse neonatal cardiomyocytes, HG conditions increased levels of Fundc1, the inositol 1,4,5-trisphosphate type 2 receptor (Ip3r2), and MAMs. Genetic downregulation of either Fundc1 or Ip3r2 inhibited MAM formation, reduced endoplasmic reticulum-mitochondrial Ca2+ flux, and improved mitochondrial function in HG-treated cardiomyocytes. Consistently, adenoviral overexpression of Fundc1 promoted MAM formation, mitochondrial Ca2+ increase, and mitochondrial dysfunction in cardiomyocytes exposed to normal glucose (5.5 mmol/L d-glucose). In comparison with nondiabetic controls, levels of Fundc1, Ip3r2, and MAMs were significantly increased in hearts from streptozotocin-treated mice and Akita mice. Furthermore, in comparison with control hearts, diabetes mellitus markedly increased coimmunoprecipitation of Fundc1 and Ip3r2. The binding of Fundc1 to Ip3r2 inhibits Ip3r2 ubiquitination and proteasome-mediated degradation. Cardiomyocyte-specific Fundc1 deletion ablated diabetes mellitus-induced MAM formation, prevented mitochondrial Ca2+ increase, mitochondrial fragmentation, and apoptosis with improved mitochondrial functional capacity and cardiac function. In mouse neonatal cardiomyocytes, HG suppressed AMP-activated protein kinase activity. Furthermore, in cardiomyocytes of Prkaa2 knockout mice, expression of Fundc1, MAM formation, and mitochondrial Ca2+ levels were significantly increased. Finally, adenoviral overexpression of a constitutively active mutant AMP-activated protein kinase ablated HG-induced MAM formation and mitochondrial dysfunction. CONCLUSIONS: We conclude that diabetes mellitus suppresses AMP-activated protein kinase, initiating Fundc1-mediated MAM formation, mitochondrial dysfunction, and cardiomyopathy, suggesting that AMP-activated protein kinase-induced Fundc1 suppression is a valid target to treat diabetic cardiomyopathy.
引用
- Wu S, Lu Q, Ding Y, et al. Hyperglycemia-Driven Inhibition of AMP-Activated Protein Kinase α2 Induces Diabetic Cardiomyopathy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes In Vivo. Circulation. 2019. PMID: 30646747. doi:10.1161/CIRCULATIONAHA.118.033552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。